The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Eribulin plus anlotinib in advanced soft tissue sarcoma (ERAS): Updates on efficacy and biomarkers.
 
Jie Liu
Honoraria - Eisai; MSD; Novartis; Roche; Shanghai Junshi BioSciences
 
Yang Fu
No Relationships to Disclose
 
Bin Wang
No Relationships to Disclose
 
Zhike Li
Honoraria - MSD, Roche, Novartis, Eisai Europe Ltd, Shanghai Junshi Biosciences Co., Ltd, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 
Ying Wang
Honoraria - MSD, Roche, Novartis, Eisai Europe Ltd, Shanghai Junshi Biosciences Co., Ltd, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 
Jie Zhang
Honoraria - MSD, Roche, Novartis, Eisai Europe Ltd, Shanghai Junshi Biosciences Co., Ltd, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 
Tingwu Yi
Honoraria - MSD, Roche, Novartis, Eisai Europe Ltd, Shanghai Junshi Biosciences Co., Ltd, and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 
Yaotiao Deng
Speakers' Bureau - Chia Tai Tianqing Pharmaceutical Group; Eisai Europe; MSD; Novartis; Roche; Shanghai Junshi BioSciences; Shenzhen Chipscreen Biosciences
 
Yu Jiang
No Relationships to Disclose